Objective: We report on our experience with a less invasive treatment for benign prostatic hyperplasia (BPH), a high–energy ‘30–minute’ treatment algorithm of transurethral microwave thermotherapy (TUMT). As initial investigators of this new device, we have tested its safety, tolerance and efficacy. Methods: From April 1998 to May 1999, all males attending our Outpatient Clinic for symptomatic BPH were evaluated with physical examination, symptoms questionnaire, bladder and prostate ultrasound scan, cystomanometry and pressure–flow study. Sixty–one males with: prostate volume >30 cm3, prostate length >25 mm, Qmax <15 ml/s, IPSS ≧13, MSS ≧8, and without excessive middle lobe, underwent one session of 30–min TUMT treatment after informed consent was obtained. Treatments were performed on an outpatient basis and with oral sedation and local analgesia. Follow–up visits were scheduled for 2 weeks, 1, 3, 6 and 12 months post–treatment. Results: Fifty–six out of 61 patients (92%) completed the 6–month follow–up visit: mean MSS improved from 12.0 to 4.3; IPSS changed from 18.1 to 5.2. The mean maximum flow rate improved from 9.1 to 17.8 ml/s and the mean post–void residual decreased from 92 to 18 ml. Cavities within prostatic tissue were observed in 54 out of 56 patients (95%). The most frequent adverse event was UTI (21.3%); no major complications were observed. Conclusion: Our experience demonstrated that 30–min TUMT is a safe, effective and well–tolerable treatment for patients with BPH and LUTS, although further studies are needed to assess result durability and long–term efficacy.

Keywords:
Prostate, Prostatic hypertrophy, Transurethral microwave thermotherapy
1.
Barry MJ: Epidemiology and natural history of benign prostatic hyperplasia. Urol Clin North Am 1990;17:495–500.
2.
Lepor H, Rigaud G: The efficacy of transurethral resection of the prostate in men with moderate symptoms of prostatism. J Urol 1990;143:553–557.
3.
de Wildt MJAM, de la Rosette JJMCH, Debruyne FMJ: Retreatment rate; in Kurth KH, Newling DWW (eds): Benign Prostatic Hyperplasia. Recent Progress in Clinical Research and Practice. New York, Wiley–Liss, 1994, pp 597–601.
4.
Milroy EJG: Prostatic stents. Curr Opin Urol 1995;5:25–28.
5.
Schulman CC, Zlotta AR: Transurethral needle ablation of the prostate: A new treatment of benign prostatic hyperplasia using interstitial low–level radiofrequency energy. Curr Opin Urol 1995;5:35–39.
6.
Madersbacher S, Kratzik C, Susani M, Marberger M: Tissue ablation in benign prostatic hyperplasia with high intensity focused ultrasound. J Urol 1994;152:1956–1959.
7.
Anson K, Watson G: The current status of the use of lasers in the treatment of benign prostatic hyperplasia. Br J Urol 1995;75(suppl 1): 34–38.
8.
Devonec M, Carter SStC, Tubaro A, de la Rosette J, Hofner K, Dahlstrand C, Perrin P: Microwave thermotherapy. Curr Opin Urol 1995;5:3–9.
9.
de la Rosette J, de Wildt M, Hofner K, Carter SStC, Debruyne FM, Tubaro A: High energy thermotherapy in the treatment of benign prostatic hyperplasia: Results of the European Benign Prostatic Hyperplasia Study Group. J Urol 1996;156:97–101.
10.
de la Rosette J, de Wildt M, Hofner K, Carter SStC, Debruyne FM, Tubaro A: Pressure–flow study analyses in patients treated with high– energy thermotherapy. J Urol 1996;156:1428– 1433.
11.
Eliasson T, Wagrell L: New technologies for the surgical management of symptomatic benign prostatic enlargement: tolerability and morbidity of high–energy transurethral microwave thermotherapy. Curr Opin Urol 2000; 10:15–17.
12.
Aso Y: Clinical research criteria; in Cockett ATK, Aso Y, Chatelain C, Denis L, Griffiths K, Khoury S, Murphy G (eds): Proceedings of the Third International Consultation on Benign Prostatic Hyperplasia, Paris 1995, pp 451–468.
13.
Carter SStC, Patel A, Royer P, Ramsay JWA, Perrin P, Devonec M: Single session transurethral microwave thermotherapy for the treatment of benign prostatic hyperplasia. J Endourol 1991;5:137–144.
14.
Dahlstrand C, Walden M, Geirsson G, Pettersson S: Transurethral microwave thermotherapy versus transurethral resection for symptomatic benign prostatic obstruction: A prospective randomized study with a 2–year follow–up. Br J Urol 1995;76:614–618.
15.
Cowles RS 3rd, Kabalin JN, Childs S, Lepor H, Dixon C, Stein B, Zabbo A: A prospective randomized comparison of transurethral resection to visual laser ablation of the prostate for the treatment of benign prostatic hyperplasia. Urology 1995;46:155–160.
16.
de la Rosette JJ, de Wildt M, Hofner K, Carter SStC, Debruyne FM, Tubaro A: High–energy thermotherapy in the treatment of benign prostatic hyperplasia: Results of the European BPH Study Group. J Urol 1996;156:97–102.
17.
de Wildt M, Debruyne FM, de la Rosette JJ: High–energy transurethral microwave thermotherapy: A thermoablative treatment for benign prostatic obstruction. Urology 1996;48: 416.
18.
Djavan B, Roehborn G, Shahrokh S, Ghawidel K, Marberger M: Prospective randomized comparison of high–energy transurethral microwave thermotherapy versus alpha–blocker treatment of patients with benign prostatic hyperplasia. J Urol 1999;161:139–143.
19.
Carter S, Tubaro A, Pace G, Tempesta A, Selvaggi FP, Cabane V – Hammersmith Hospitals Trust, London, UK, L’Aquila, Italy, Bari, Italy and Vaulx en Velin, France: Intraprostatic temperatures in a new generation of microwave thermotherapy. Br J Urol 1999;83(suppl 4): 136.
20.
Francisca EA, Kortmann BB, Floratos DL, Kiemeney LA, Debruyne FM, de la Rosette JJ: Tolerability of 3.5 versus 2.5 high–energy transurethral microwave thermotherapy. Eur Urol 2000;38:59–63.
21.
Riehmann M, Kues JM, Madsen PO, Bruskowitz RC: Transurethral resection versus incision of the prostate: A randomized, prospective study. Urology 1995;45:768–775.
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.